

AD \_\_\_\_\_

MIPR NO:

95MM5535

TITLE:

Clinical Impact of Hepatitis C Infection in Military Active Duty women

PRINCIPAL INVESTIGATOR:

COL Maria H. Sjogren, MD

CONTRACTING ORGANIZATION:

Walter Reed Army Medical Center  
Washington, DC 20307-5001

REPORT DATE:

30 September 1995

TYPE OF REPORT:

Annual

PREPARED FOR:

U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960129 015

DTIC QUALITY INSPECTED 1

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>	<b>2. REPORT DATE</b> 30 September 95	<b>3. REPORT TYPE AND DATES COVERED</b> Annual 1 Dec 94 - 1 Aug 95	
<b>4. TITLE AND SUBTITLE</b> Clinical Impact of Hepatitis C Infection in Military Active Duty Women		<b>5. FUNDING NUMBERS</b> 95MM5535	
<b>6. AUTHOR(S)</b> COL Maria H. Sjogren, MD			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Walter Reed Army Medical Center Washington, DC 20307-5001		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>			
<b>12a. DISTRIBUTION/AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited		<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b> To determine the rate of hepatitis C infection among active duty women, 932 volunteers were enrolled in the study. Subjects were grouped under 3 categories: 463 healthy women, 388 women who visit outpatient clinics and 81 women who are hospitalized for a variety of diagnosis. Demographic data and serologic diagnosis of the infection were conducted. Serological assays were: a marker of liver disease: alanine aminotransferase (ALT) and specific markers of HCV infection: antibody to HCV by ELISA and recombinant immunoblot assay. Data are being analyzed at the present time and results are preliminary. 932 women in active duty, aged between 18 and 54 years participated. Among the 932, 420 were officers and 512 were enlisted. Overall, 25 (2.7%) of the volunteers had abnormal ALT levels, the distribution was 1.5% among healthy women, 2.83% among clinic patients and 8.64% among inpatients. Similarly approximately 25 (2.7%) serum specimens tested positive for antibody to hepatitis C. HCV antibody were tested under code and we are in the process of analyzing the results to establish statistical correlations. In summary, active duty women have evidence of abnormal ALT which increases when disease is present. HCV-infection (2.7%) is seen in excess than the rate observed among healthy American blood donors (0.5%).			
<b>14. SUBJECT TERMS</b> HCV infection, Women's Health, Hepatitis Defense Women'S Health Research		<b>15. NUMBER OF PAGES</b> 9	
		<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

**Block 1.** Agency Use Only (Leave blank).

**Block 2.** Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3.** Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4.** Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5.** Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

**Block 6.** Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7.** Performing Organization Name(s) and Address(es). Self-explanatory.

**Block 8.** Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9.** Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

**Block 10.** Sponsoring/Monitoring Agency Report Number. (If known)

**Block 11.** Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a.** Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b.** Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13.** Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14.** Subject Terms. Keywords or phrases identifying major subjects in the report.

**Block 15.** Number of Pages. Enter the total number of pages.

**Block 16.** Price Code. Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19.** Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20.** Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

*ms* For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

*Manuel H. Ayres*      30 Sept 95  
\_\_\_\_\_  
PI - Signature                      Date

# CLINICAL IMPACT OF HEPATITIS C INFECTION IN MILITARY ACTIVE DUTY WOMEN

## TABLE OF CONTENTS

	Page
Introduction	1
Body of the report	2
Conclusions	3
References	3
Appendix	4,5

## INTRODUCTION

Hepatitis C virus (HCV) infection is a common infection in the United States. About 0.3% of American blood donors (1) and 1.4% of apparently healthy Americans test positive for the virus (2). Statistically, these rates will correspond to a reservoir of approximately 3.5 million HCV infected persons in the United States (2). HCV leads to progressive liver disease, including cirrhosis in 20% of infected individuals. In addition approximately 20% of cirrhotics will develop hepatocellular carcinoma. There is little information about the prevalence or morbidity of the infection in women. Published clinical trials of interferon-alpha, the only approved therapeutic drug, show an 80% enrollment of men. This research effort attempts to minimize this gap in knowledge.

Healthy women and diseased women will be studied. Further more, enrollment of women who are ill, would be recruited in two categories, outpatient and inpatient. This distinction could serve as a measure of magnitude of disease status. All volunteers will be asked to answer a questionnaire and donate a blood sample. The questionnaire will collect basic demographic data such as age, race and MOS. In addition known risk factors for HCV will be asked such as past history of blood transfusions, intravenous drug abuse, sexual promiscuity, past history of liver disease, increased alcohol intake, etc. The blood sample will be used to test for alanine aminotransferase, a marker of liver disease and for hepatitis C serological markers. Once data are collected, statistical analysis would be carried out. Primary goal is to observe rates of hepatitis C infection in these three groups of active duty women.

## BODY OF THE REPORT

The experimental methods used to accomplish this research were as follows:

Active duty women were recruited from 3 different categories: healthy women, women who sought medical advice as outpatients and women who were hospitalized for a variety of medical diagnosis. Women with previous known liver disease were excluded.

Written questionnaire obtained from each volunteer , where the following questions were asked:

Demographic data: age, race, military rank

Epidemiological risks for hepatitis C infection: Occupation, MOS, history of blood transfusion, history of intravenous drug abuse, sexual promiscuity.

Serological data:

A serum sample was obtained from each volunteer to test for alanine aminotransferase (ALT) as a non-specific marker of liver disease.

Sera were also tested for specific markers of hepatitis C virus infection: antibody against the virus by ELISA and recombinant immunoblot assay.

Sera which was found to be positive by the antibody assay will be tested for HCV RNA. HCV RNA is a test of viral replication. In addition, the HCV viral genotype will be assessed in each positive sample.

## RESULTS

Recruitment is still ongoing and the results discussed below are preliminary in nature.

To date 932 volunteers have been recruited.

463 are healthy active duty women

388 are active duty women who visited an outpatient clinic

81 were active duty women hospitalized for a variety of diagnosis

The women were aged between 18 and 54 years, 420 were officers and 512 enlisted.

The racial distribution were as follows, 59% Caucasians, 29% African Americans, 7% Hispanics, 3% Asian and 2% belong to other ethnic groups.

Correlations between risk factors and HCV infection are in progress.

### **Alanine aminotransferase:**

Of the 932 women 25 (2.7%) had abnormal serum ALT levels. The abnormality correlated with the health status of the individuals. 7/463 (1.5%), 11/388 (2.83%) and 7/81 (8.64%).

### **Hepatitis C tests:**

Sera were tested under code and we only have the overall results, 25 volunteers were discovered to be infected with HCV, for an overall infection rate of 2.7%. Correlation with ALT, risk factors, demographic data and health status is in progress.



## CONCLUSIONS

The conclusions are preliminary because the work has not been completed. However, it is clear that hepatitis C has increased rates of infection among active duty military women. Data from comparable American populations show that about 0.3% to 0.5% of blood donors are infected with the virus (1). A serological survey of apparently healthy American population (not blood donors) was recently shown to have a 1.4% overall rate of infection (2). This study shows an overall infectivity rate of 2.7%. It will be of interest to observe if the ALT abnormality which was also observed in 2.7% of the studied subjects, correlates with the positive tests for HCV infection. The observation of abnormal serum ALT levels which correlated with status of health is quite interesting. It is possible that healthy women have less risk to acquire HCV infection than their counterparts who attend clinics or become hospitalized. Surgical procedures, blood transfusions, and other risk factors associated with medical care may play a role in transmission of HCV. A similar study to address military populations away from hospital centers is indicated. No major studies have been published since the beginning of this effort which addressed the topic of this research. Perhaps the only relevant work is by Thomas et al, which showed an increased rate of infection among women whose sexual partners are infected with the virus (3). Women had a 3.7 times more likelihood to be infected with HCV. In conclusion, military active duty women have an increased rate of hepatitis C infection as compared to American blood donors or counterpart civilian populations. Women also manifested a susceptibility to express liver disease, manifested by abnormal serum ALT levels. This occurs when they become ill and seek medical care as inpatients or outpatients. Data are being analyzed to examine possible risk factors which would explain such findings.

## REFERENCES

1. Kleinman S, Alter HJ, Busch M et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. *Transfusion* 1992;32:805-813
2. Alter MJ. Hepatitis C in the West. *Seminars of Liver Disease* 1995;15:5-14
3. Thomas DL, Zenilman JM, Alter HJ et al. Sexual transmission of hepatitis C virus among patients attending Baltimore sexually transmitted diseases clinics. An analysis of 309 sexual partnerships. *J Infect Dis* 1995;171:768-775

# Clinical Impact of HCV Infection Among Military Women Demographic Data




n= 932

Sjogren 95

# Clinical Impact of HCV Infection Among Military Women

## Abnormal ALT per Group of Subjects (%)



Sjogren 95